Document is current
Any future updates will be listed below
-
Authors
Campanella, Gabriele https://orcid.org/0000-0001-6299-1311
Kumar, Neeraj
Nanda, Swaraj
Singi, Siddharth https://orcid.org/0009-0005-6184-5239
Fluder, Eugene
Kwan, Ricky
Muehlstedt, Silke
Pfarr, Nicole https://orcid.org/0000-0002-5977-5375
Schüffler, Peter J. https://orcid.org/0000-0002-1353-8921
Häggström, Ida https://orcid.org/0000-0001-9178-6683
Neittaanmäki, Noora https://orcid.org/0000-0002-8733-5510
Akyürek, Levent M.
Basnet, Alina https://orcid.org/0000-0002-0062-9007
Jamaspishvili, Tamara https://orcid.org/0000-0002-1475-5717
Nasr, Michel R.
Croken, Matthew M.
Hirsch, Fred R.
Elkrief, Arielle
Yu, Helena https://orcid.org/0000-0002-0377-9510
Ardon, Orly https://orcid.org/0000-0001-8147-933X
Goldgof, Gregory M.
Hameed, Meera
Houldsworth, Jane https://orcid.org/0000-0002-6781-1700
Arcila, Maria https://orcid.org/0000-0001-5824-6554
Fuchs, Thomas J. https://orcid.org/0000-0001-7603-8687
Vanderbilt, Chad https://orcid.org/0000-0002-8114-0237
-
Funding
Funding for this research was provided by:
Warren Alpert Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA008748)
- License Information
-
More Information
Article History
Received: 5 November 2024
Accepted: 19 May 2025
First Online: 9 July 2025
Competing interests
: C.V. and T.J.F. report intellectual property rights and equity interest in Paige.AI, Inc. T.J.F. is employed by Eli Lilly. F.R.H. has acted as an adviser of Amgen, AstraZeneca, Bicara Therapeutics, BMS, Daiichi, G1 Therapeutics, Genentech/Roche, Genzyme/Sanofi, GSK, Merck, Merus Therapeutics, Nectin Therapeutics, NextCure, Novartis, OncoCyte, Oncohost and Regeneron. H.Y. has received consulting fees from AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Genentech/Roche, Janssen, Merus, Pfizer, Regeneron, Ribon Therapeutics and Turning Point Therapeutics. M.H. holds fiduciary roles with the International Society of Bone and Soft Tissue Pathology and the United States & Canadian Academy of Pathology (USCAP). M.A. holds a fiduciary role with the Association for Molecular Pathology, has provided professional services for Biocartis US, Inc. and PER Events, LLC, and has intellectual property rights associated with SOPHiA. A.E. declares research grant support from Kanvas Bioscience, GMT Bioscience, BMS, Merck and Astrazeneca, and consulting and honoraria from BMS, Merck, Astrazeneca and EMD SorenoGENETICS. All disclosed competing interests are outside of the submitted work. G.C., N.K., S.N., S.S., E.F., R.K., S.M., N.P., P.J.S., I.H., N.N., L.M.A., A.B., T.J., M.R.N., M.M.C., O.A., G.M.G. and J.H. have no competing interests.
